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Improvements in management of cystic fibrosis (CF) through specialist centres in the UK have been 
associated with a step-change in life expectancy. With increasing numbers of adult patients there is 
a need to review health care provision to ensure it is sufficient to meet future needs. We used UK CF 
Registry data to project the number of patients aged 16–17 and 18 and older  up to 2030, and numbers 
therefore requiring specialist adult CF care. Survival modelling was used to estimate age-specific 
mortality rates. New-diagnosis rates were estimated using diagnoses observed in the Registry and 
national population figures. Uncertainty in projections was captured through 95% prediction intervals 
(PI). The number of adults (aged 18 and older) is expected to increase by 28% from 6,225 in 2017 to 
7,988 in 2030 (95% PI 7,803–8,169), assuming current mortality rates. If mortality rates improve at 
the rate seen over recent years, the projected number increases to 8,579 (95% PI 8,386–8,764). The 
age distribution is also expected to change, with 36% of CF adults being over 40 in 2030, versus 21% in 
2017. There is an urgent requirement to review adult CF health care provision, due to both increasing 
numbers and the changing care needs of an older population.
Improvements in management of cystic fibrosis (CF) delivered in specialist centres in the United Kingdom 
(UK) have been associated with an overall step-change in CF, from a fatal disease of childhood in the 1960s and 
1970s to a disease requiring long-term management through adulthood in the twenty-first  century1. The UK CF 
Registry is a key resource for monitoring of patient numbers and outcomes, and according to current registry-
based statistics, half of babies born today with CF in the UK are expected to survive beyond the age of  472–4. As 
a consequence of improving survival, the number of adult CF patients has  increased5,6. With increasing numbers 
of adult patients there is a need to review health care provision to ensure it is sufficient to meet the needs of the 
evolving CF population over the coming years. The UK has provided world leadership in the development of 
adult specialist centre care, separate from  paediatrics7 and the European Respiratory Society published a task 
force report jointly with the European CF Society endorsing the UK approach to specialist  care8. However, there 
is growing recognition that care needs may soon need to evolve further, as co-morbidities change and novel 
effective therapies are  introduced9.
This work used data from the UK CF Registry and the Office of National Statistics (ONS) to obtain projec-
tions of future numbers of adult CF patients (aged 18 and older) up to 2030. We also provide estimates of the 
number of patients requiring care through specialist adult CF centres, which includes some patients aged 16 
and 17. Future numbers depend on the current numbers of adults with CF, numbers of children with CF who 
will transition to the over 18 age group in time, numbers of new diagnoses, and age-specific mortality rates. 
The focus is on estimating the number of individuals aged 16 years and older and we present projections of 
the numbers of patients aged 16–17 and aged 18 and older. To estimate the number who will require care in a 
specialist adult CF centre we assume that all individuals aged 19 years and older and one third of those aged 16, 
17 and 18 are treated in such a centre, as the transition to adult care occurs over this 3 year period. As the transi-
tion process is affected by a number of clinical, practical and logistical issues, we took a pragmatic approach by 
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evenly distributing the numbers over this 3 year age range. Alongside the estimates of future patient numbers, 
we provide 95% prediction intervals to quantify the uncertainty in the estimates. Our work is closely related to 
that of Burgel et al.6, who obtained forecasts of patient numbers in 34 countries in Europe using data from the 
European CF Society Patient Registry. Their model forecasted an increase in the UK adult CF population (aged 18 
and older) from 4,950 in 2010 to 8,876 in 2025, an increase of 76%. We hypothesised that their UK forecasts could 
be overestimates due to using over-estimates of the rate of new diagnoses, whereby new individuals appearing 
in the registry were counted as new diagnoses. The study made use of UK data captured over a period in which 
the UK CF Registry data acquisition methods changed, as a result of changes in the NHS commissioning of care 
and requirements for data collection, meaning that new individuals captured in the Registry were not necessarily 
new diagnoses. We avoid this by making use of diagnosis dates as well as dates of birth and death, together with 
use of UK population forecasts. We compare our findings with those of Burgel et al.
Our results quantify the expected impact of sustained improvements in survival in CF on the population of 
individuals living with this condition up to 2030, and on the age distribution of the population. The results inform 
health care provision in the UK, to facilitate planning of service requirements in the presence of a larger CF 
population and increasing numbers of individuals reaching older ages. Furthermore, the methodology presented 
provides an approach to obtaining population projections using data from other disease registries and electronic 
health records, including how to incorporate estimates of uncertainty into the projections.
Materials and methods
Data.  The primary resource for this study was the UK CF Registry. The UK CF Registry is a national, secure 
database sponsored and managed by the Cystic Fibrosis  Trust10. It was established in 1995 and records demo-
graphic data and longitudinal health data on nearly all people with CF in the UK, to date capturing data on over 
12,000 individuals. The Registry includes > 99% of individuals with CF in the  UK10, making it a reliable resource 
for establishing current numbers of individuals with CF and for estimating quantities needed to derive popula-
tion projections. Data are collected in a standardized way at designated (approximately) annual visits on over 
250 variables in several domains, and have been recorded using a centralised database since 2007. This study 
makes use of dates of birth, diagnosis and death for individuals observed between 1996 and 2017. Dates of birth 
and death are provided in month–year format and the day was set to be the 15th of the month, following stand-
ard practice in survival analyses using UK CF Registry data.
To estimate expected numbers of new diagnoses in future years we required estimates of rates of new diag-
noses by age and estimates of the size of the UK population up to 2030. To estimate rates of diagnosis we used 
numbers of new diagnoses from the UK CF Registry combined with ONS data on the size of the UK popula-
tion by age up to  201711. ONS projections of the population size from 2018 to 2030 were used to project future 
numbers of  diagnoses12.
Statistical methods: overview.  A detailed description of the statistical analysis is given in the Supple-
mentary Material. Here we provide an overview of the approach. The basis of the analysis is to estimate the num-
ber of individuals of each age a (a = 16, 17,…,100) at the start of each calendar year from 2018 to 2030. These are 
then added together to provide an estimate of the total number of individuals aged 16–17 and the total number 
aged 18 and older at the start of each year.
The estimated number of patients aged a + 1 at the start of 2018 is the observed number aged a at the start of 
2017 who survive for 1 year, plus the observed number of new diagnoses at age a in 2017 who survive to the start 
of 2018. New diagnoses are all assumed to occur at the start of a given year, and so the number of individuals 
diagnosed at age a in 2017 who survive to the start of 2018 is the number who survive 1 year. To estimate the 
number of individuals aged a + 1 at the start of 2019 we make use of the projected number of individuals aged 
a at the start of 2018 and the projected number of newly diagnosed individuals in 2018, alongside the 1-year 
survival probabilities. This is repeated year by year up to 2030. Individuals aged 3 years in 2017 will be aged 16 
in 2030, and so the analysis requires numbers of individuals aged 3 years and older in 2017. Similarly, we need 
to take account of new diagnoses aged 4 years and older in 2018, aged 5 and older in 2019, and so on, up to 
age 15 and older in 2029. We do not need to incorporate information on newborn diagnoses or diagnoses in 
children aged under 3 years, because no children aged under 3 in 2017 (or later) will reach age 16 by 2030, the 
end of our forecast period.
Statistical methods: estimating diagnosis and mortality rates.  The analysis requires estimates of 
the probability of survival to age a + 1 conditional on survival to age a from each age a (a = 3,...,100). These prob-
abilities were estimated using the UK CF Registry data using a flexible parametric survival  model13, following 
the approach used by Keogh et al.4. This made use of dates of birth, diagnosis and death. Age of diagnosis and 
death were derived and the time scale for the survival analysis was age. Individuals who do not have a recorded 
date of death were censored at the end of 2017.
The analysis also requires estimated numbers of new diagnoses at each relevant age in each calendar year from 
2018 to 2030. Age-specific diagnosis rates were estimated using UK CF Registry data on the number of individu-
als diagnosed at each age during 2013–2017 and the number of individuals in the UK population over the same 
period using ONS population  data11. The number of new diagnoses is small at all ages, so we considered new 
diagnoses in 5-year age groups, with diagnoses at ages 63 and older being combined due to very small numbers. 
The probability of diagnosis during a 1-year period was estimated for each age group as the number of diagnoses 
divided by the number in the UK population. The analysis uses the projected number of individuals in the UK 
population at each age in years from 2018–2030 multiplied by the diagnosis rates to obtain yearly numbers of 
new diagnoses at each relevant age. It is assumed that age-specific diagnosis rates will remain similar up to 2030.
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The analysis outlined above makes the assumption that age-specific mortality rates will remain the same up 
to 2030. We also derived population projections under conditions whereby recent decreases in mortality rates 
continue in the future. Specifically, we estimated the linear downward trend in mortality rates over the 10-year 
period 2008–2017, and applied this to obtain projections under the assumption that mortality rates continue 
to decrease at the same rate in the future, or half that rate. This is similar to the approach used by Keogh et al. 4 
and MacKenzie et al.14.
As a sensitivity analysis the analysis was repeated separately in males and females, since females have been 
shown to have worse survival than  males2,4. Mortality rates were estimated separately by sex. Diagnosis rates 
were assumed to be the same in males and females and half of new diagnoses were assumed to be in males and 
half in females.
We obtained 95% prediction intervals (95% PI) for the projected population numbers using an extended 
bootstrapping  approach15,16. The true future numbers are expected to lie within the 95% prediction interval 
with probability 0.95.
Results
A total of 12,904 individuals were recorded in the UK CF Registry between its starting year of 1996 and 2017, 
the most recent year of available data. Over the 10 year period from 2008 to 2017 the number of people aged 
18 and older increased by 44% from 4,313 to 6,225, while the number of 16–17 year olds decreased from 627 to 
483. Table 1 shows the number of new diagnoses during 2013–2017 by age group alongside the number at those 
ages in the underlying UK population, and the resulting estimated diagnosis rates. In the youngest age group, 
3–7 years, the diagnosis rate was estimated to be 1.54 per million. Diagnosis rates are higher in children and 
decreased with age. There were no observed new diagnoses after age 81 during 2013–2017 and the new diagnosis 
rate was assumed to be zero beyond this age.
Figure 1 shows the estimated survivor curve obtained using data from 2013–2017. The full specification of 
the model and corresponding parameter estimates are provided in the Supplementary Materials. This model 
aligns closely with that of Keogh et al.4, but was fitted for the more recent period 2013–2017. Supplementary 
Table 2 shows the model-based estimated 1-year survival probabilities from ages 3–100, which are used in the 
projection algorithm.
Table 2 shows the projected numbers of patients aged 16–17 and aged 18 and older for 2018–2030, and cor-
responding 95% prediction intervals, alongside the observed numbers from 2013–2017. The total number of 
individuals aged 16–17 is expected to increase by 20% from 483 in 2017 to 578 (95% PI 562–595) in 2030, and the 
number of individuals aged 18 and older is expected to increase by 28% from 6,225 to 7,988 (95% PI 7,803–8,169) 
over the same period. The 95% prediction intervals indicate that the actual number of adult CF patients in 2030 
is expected lie in the range from 7,803 to 8,169 with probability 0.95. Under the assumption that all individuals 
aged 19 and older and one-third of patients aged 16–18 require care in an adult CF centre, we estimate that the 
total number of individuals requiring adult care will increase from 6,212 in 2017 to 7,981 (95% PI 7,797–8,162) 
in 2030, an increase of 28% (95% PI 26–31%).
Figure 2 compares the observed age-distribution of patients aged 16 and older in 2017 with the projected age 
distribution in 2030. This indicates a significant change in the shape of the distribution. In 2030 it is expected that 
a greater percentage of the adult CF population will be older adults. In 2017, 49% of adult (aged 18 and older) 
were aged over 30, and 21% were aged over 40. In 2030, it is projected that 63% of adults (aged 18 and older) will 
be aged over 30, and 36% will be aged over 40.
The above results are based on an assumption that current mortality rates will hold in the future. Using data 
from 2008–2017 it was estimated that age-specific mortality rates decreased by 3% per calendar year [hazard ratio 
0.967 (95% CI 0.949, 0.987)]. Table 3 shows the impact on projected numbers if the mortality rates continued to 
Table 1.  Observed numbers of new diagnoses by age group (defined by 5-year age groups, with ages 63 
onwards being combined into a single group) from 2013–2017, number of individuals in the UK population 
during the same period based on ONS statistics, and the ratio (estimated diagnosis rate).
Age group Number of new diagnoses Number in the UK population Estimated diagnosis rate
3–7 31 20,183,682 1.54E−06
8–12 35 18,525,594 1.89E−06
13–17 29 18,289,582 1.59E−06
18–22 24 20,426,605 1.17E−06
23–27 27 22,206,310 1.22E−06
28–32 20 22,020,185 9.08E−07
33–37 37 21,244,044 1.74E−06
38–42 28 20,504,753 1.37E−06
43–47 20 22,723,270 8.80E−07
48–52 12 23,245,834 5.16E−07
53–57 11 21,024,065 5.23E−07
58–62 13 18,257,724 7.12E−07
63–81 19 52,878,448 3.59E−07
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decrease by the same amount each year up to 2030, and if they decreased by half that amount. If mortality rates 
continue to decrease at the same rate, the projected number of adults in 2030 would be expected to increase by 
38% (95% PI 35–41%) to 8,579 (95% PI 8,386–8,764). If mortality rates decreased at half that rate, the projected 
number projected number of adults in 2030 would be expected to increase by 35% (95% PI 32–38%) to 8,390 
(95% PI 8,187–8,588). The projected numbers requiring care in an adult specialist centre would be expected to 
increase by similar percentages (see Supplementary Table 3).
Breaking the results down by sex (Supplementary Table 4), the number of adult females with CF is expected 
to increase by 29% from 2,798 in 2017 to 3,619 (95% PI 3,497–3,739) in 2030, and the number of adult males is 
estimated to increase by 27% from 3,427 to 4,368 (95% PI 4,246–4,481) over the same time period. The number 
Figure 1.  Estimated survivor curve using UK CF Registry data from 2013–2017. The black curve is from the 
flexible parametric survival model. The grey line shows the Kaplan–Meier estimates for comparison. Dotted 
lines indicate 95% confidence intervals.
Table 2.  Observed (2013–2017) and projected (2018–2030) numbers of people with CF aged 16–17, aged 18 
and older and the expected total number of individuals requiring adult care (calculated as the number aged 
19 and older plus one third of the number aged 16–18). All projected numbers were rounded to the nearest 
integer, with corresponding 95% prediction intervals a Total number requiring care in an adult centre is the 
number aged 19 and older plus one third of the number aged 16, 17 or 18.
Year
Total aged 16–17 Total aged 18 and older
Total requiring care in an adult 
 centrea
Number 95% prediction interval Number 95% prediction interval Number 95% prediction interval
2013 582 – 5,492 – 5,493 –
2014 559 – 5,700 – 5,688 –
2015 539 – 5,909 – 5,901 –
2016 526 – 6,098 – 6,092 –
2017 483 – 6,225 – 6,212 –
2018 492 (488, 497) 6,390 (6,361, 6,418) 6,379 (6,350, 6,407)
2019 476 (470, 483) 6,505 (6,460, 6,548) 6,518 (6,474, 6,561)
2020 442 (435, 450) 6,669 (6,610, 6,726) 6,635 (6,577, 6,692)
2021 492 (483, 501) 6,759 (6,688, 6,829) 6,788 (6,717, 6,858)
2022 491 (481, 502) 6,881 (6,797, 6,963) 6,886 (6,802, 6,968)
2023 493 (482, 505) 7,011 (6,914, 7,106) 7,008 (6,912, 7,103)
2024 544 (532, 556) 7,124 (7,014, 7,231) 7,147 (7,037, 7,254)
2025 558 (545, 572) 7,248 (7,126, 7,368) 7,265 (7,143, 7,385)
2026 539 (525, 554) 7,402 (7,268, 7,534) 7,390 (7,256, 7,522)
2027 601 (587, 617) 7,532 (7,385, 7,676) 7,554 (7,407, 7,698)
2028 631 (615, 647) 7,659 (7,499, 7,815) 7,690 (7,530, 7,846)
2029 611 (595, 628) 7,841 (7,669, 8,010) 7,825 (7,653, 7,993)
2030 578 (562, 595) 7,988 (7,803, 8,169) 7,981 (7,797, 8,162)
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Figure 2.  Distribution of ages of people with CF aged 16 and older: based on observed numbers for 2017 and 
projected numbers for 2030.
Table 3.  Observed (2013–2017) and projected (2018–2030) total numbers of adults (aged 18 and older) with 
CF, with corresponding 95% prediction intervals for projected numbers: (a) Assuming mortality rates do not 
change over time; (b) Assuming mortality rates improve at half the rate as during 2008–2017; (c) Assuming 
mortality rates improve at the same rate as during 2008–2017.
(a) Assuming mortality rates do not 
change
(b) Assuming mortality rates 
improve at half the rate as during 
2008–2017
(c) Assuming mortality rates 
improve at the same rate as during 
2008–2017
Year Number 95% prediction interval Number 95% prediction interval Number 95% prediction interval
2013 5,492 – 5,492 – 5,492 –
2014 5,700 – 5,700 – 5,700 –
2015 5,909 – 5,909 – 5,909 –
2016 6,098 – 6,098 – 6,098 –
2017 6,225 – 6,225 – 6,225 –
2018 6,390 (6,361, 6,418) 6,405 (6,376, 6,433) 6,407 (6,378, 6,435)
2019 6,505 (6,460, 6,548) 6,538 (6,492, 6,582) 6,544 (6,498, 6,588)
2020 6,669 (6,610, 6,726) 6,723 (6,661, 6,781) 6,735 (6,674, 6,793)
2021 6,759 (6,688, 6,829) 6,835 (6,759, 6,908) 6,856 (6,781, 6,927)
2022 6,881 (6,797, 6,963) 6,982 (6,893, 7,069) 7,013 (6,924, 7,098)
2023 7,011 (6,914, 7,106) 7,141 (7,036, 7,241) 7,184 (7,081, 7,281)
2024 7,124 (7,014, 7,231) 7,284 (7,166, 7,399) 7,342 (7,226, 7,452)
2025 7,248 (7,126, 7,368) 7,442 (7,309, 7,571) 7,517 (7,387, 7,639)
2026 7,402 (7,268, 7,534) 7,633 (7,485, 7,774) 7,726 (7,584, 7,861)
2027 7,532 (7,385, 7,676) 7,801 (7,640, 7,957) 7,915 (7,760, 8,062)
2028 7,659 (7,499, 7,815) 7,969 (7,794, 8,139) 8,106 (7,938, 8,266)
2029 7,841 (7,669, 8,010) 8,196 (8,007, 8,380) 8,358 (8,178, 8,531)
2030 7,988 (7,803, 8,169) 8,390 (8,187, 8,588) 8,579 (8,386, 8,764)
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of females requiring specialist adult care is expected to increase by 35% from 2,792 in 2017 to 3,761 in 2030 (95% 
PI 3,667–3,856), and the number of males is by 23% from 3,419 to 4,220 (95% PI 4,114–4,324).
Discussion
We have used UK CF Registry data to obtain projections of numbers of CF patients aged 16 years and older up 
to 2030. Results show that the expected number of adults (aged 18 and older) with cystic fibrosis is expected to 
increase by 28% from 6,212 in 2017 to 7,981 in 2030 (95% PI 7,797–8,162). This assumes no improvements in 
mortality rates. If mortality rates continue to improve at the rate seen over the recent 10 year period, the number 
would increase to 8,572 (95% PI 8,379–8,756), which is a 38% increase. We also showed how the age distribution 
of people with CF is expected to change in the coming years, such that there is expected to be a greater propor-
tion of patients at older ages.
As noted in the introduction, our work is closely related to that of Burgel et al.6, who obtained forecasts of 
patient numbers in 34 countries in Europe using data from the European CF Society Patient Registry. As we 
had hypothesised, our estimates of future adult patient numbers are lower than those obtained by Burgel et al., 
and this is thought to be due to their counting of new individuals appearing in the registry during a period of 
improving data capture as new diagnoses. They forecasted 8,876 adult CF patients in the UK in 2025, compared 
with our estimate of 7,248 (95% PI 7,126, 7,368). The key difference between the two studies is that we made use 
of diagnosis dates observed in the Registry and UK population forecasts to estimate diagnosis rates, whereas 
Burgel et al. did not have access to this information and assumed that new individuals observed in the data in a 
given year were due to new diagnoses. Our methodology differed slightly: they estimated age-specific mortal-
ity rates non-parametrically, compared with our flexible parametric approach. This is not thought to have had 
a major impact on results as the methodological approaches are conceptually similar, involving estimation of 
how the population flows from one year to the next by estimating how many individuals flow into and out of 
the population each year. Burgel et al.17 updated their earlier results for France, including alterations to account 
for possible over-estimates of new diagnoses in the earlier work, which was attributed in part to changes in the 
population coverage of the registry data.
A major strength of our analysis is that we had access to dates of birth, diagnosis and death from the UK CF 
Registry from 1996 up to the end of 2017. Strengths of our analytical approach are that we made use of ONS 
statistics to obtain realistic diagnosis rate estimates and that we obtained prediction intervals to quantify the 
uncertainty in our estimates. Furthermore, we performed sensitivity analyses to assess the potential impact of 
future improvements in mortality rates. Limitations are that UK population forecasts are made up of different 
ethnic groups who are at different risk of CF due to genetic differences, and hence the denominator used to 
estimate diagnosis rates may have been too high. We also assumed that age-specific diagnosis rates will remain 
similar up to 2030. Diagnosis rates at older ages could, however, increase gradually over time with better diag-
nostic techniques and more extensive genotyping identifying more individuals with atypical CF. Our assump-
tions around diagnosis rates are not thought to have had an important impact on the results, since the survival 
of existing people already known to have CF is the main driver behind the increased projected numbers, rather 
than new diagnoses.
We did not account in our analysis for the impact of new and future CFTR modulators on survival. Ivacaftor 
is now used by at least 7% of the UK CF population since its introduction in  201218. Although improvements in 
mortality rates for this subset of the population will have been incorporated into our survival model, we did not 
look separately by genotype in order to obtain the projections. Recently (2019) reimbursement for the modula-
tors lumacaftor/ivacaftor (Orkambi) and tezacaftor/ivacaftor (Symkevi) has been agreed in the UK, providing 
access to a much greater proportion of patients (> 50%), however the effect these therapies have on survival 
trends will not have been captured by our analyses. Of greater importance will be the impact of so called ‘triple 
therapy’ (elexacaftor/ivacaftor/tezacaftor)—this highly effective CFTR modulator therapy produced very impres-
sive results in clinical trials and will be potentially prescribed to up to 90% of the CF  population19,20. In future 
work it will be important to stratify analyses by genotype and account for the impact of these new treatments. The 
statistical methods described in this paper could be used in conjunction with estimates of the impact of CFTR 
modulators on mortality rates, when they become available, to estimate numbers of future patients accounting 
for these developments. However, predicting this impact on adults – at least in the medium term—is likely to 
be very challenging as the majority have established and sometimes advanced, multimorbid, disease, which 
modulators will likely slow at best, so respiratory failure and the associated high care needs (e.g. non-invasive 
ventilation) will still  develop21. An ageing CF population is already bringing new challenges, such as increas-
ing diabetes, liver disease and  cancer22–24. We do not yet know the long-term effect CFTR modulators will have 
on these. Therefore, the need for specialist care is going to continue to be very relevant but will clearly need to 
evolve in these changing times.
Data from the 2017 UK CF Registry Annual  Report2 show that care was provided for adults in 26 specialist 
centres. Our findings suggest an urgent requirement to review health care provision for adults with CF in the 
UK as numbers increase, disease characteristics change and new therapies are introduced. It will be important 
to ensure there is capacity to transition more patients from paediatric care, but perhaps more importantly will 
be the ability to care for a growing proportion of older, increasingly complicated adults, and also perhaps a 
more stable younger cohort who will predominantly require outpatient-based care. Innovative technologies 
with remote monitoring may also be important here. With increasing numbers of patients, many of whom will 
lead busy active lives despite their comorbidities, we believe these data provide the vital impetus to act now to 
ensure care provision has the capacity and is fit for purpose for the changing needs of this adult CF population.
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Data availability
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